ECLIPSE AF data highlights safety and efficacy of Centauri system for atrial fibrillation treatment.
CardioFocus has announced promising results from its ECLIPSE AF study, evaluating the Centauri pulsed field ablation (PFA) system. The trial demonstrated high success rates in treating atrial fibrillation (AF) with durable and safe outcomes.
Study Highlights
- Patient Cohort:
- 82 patients treated across two European centers.
- Included individuals with paroxysmal and persistent AFib.
- Key Results:
- 90.2% 12-month freedom from clinically significant atrial arrhythmia in paroxysmal AF patients.
- 80.2% 12-month freedom from arrhythmia across all patient groups.
- Chronic PVI durability of 89% per pulmonary vein in optimized PFA cohorts.
- System Features:
- Open-platform design supporting focal contact force catheter workflows.
- Custom monopolar waveform eliminates microbubbles and muscle stimulation.
- Compatible with Abbott, Boston Scientific, and Johnson & Johnson focal ablation catheters.
Future Outlook
Steve Ogilvie, CEO of CardioFocus, emphasized the company’s focus on optimizing PFA technology:
“We customize our proprietary pulsed electric field waveforms to improve patient outcomes, and we are thrilled with the excellent results in the ECLIPSE AF clinical study.”
CardioFocus is also advancing its OptiShot PFA balloon, a next-generation ultra-compliant device currently under development.
Follow MEDWIRE.AI for updates on the latest advancements in electrophysiology and pulsed field ablation technologies.
